BRISBANE, Calif.--(BUSINESS WIRE)--āshibio, a privately held biotechnology company developing novel therapeutics for the treatment of bone and connective tissue disorders, exited stealth mode today ...

A new study explores the potential of fibroblast growth factor receptor (FGFR) antagonists in restoring defective mandibular bone repair in mouse models of osteochondrodysplasia, a group of genetic ...

Skeletal conditions such as developmental dysplasia of the hip (DDH), osteoporosis, and osteoarthritis affect millions worldwide, often causing chronic pain and disability. These disorders stem from ...

Gain-of-function mutations in fibroblast growth factor receptor (FGFR) genes are known to cause a range of skeletal disorders, such as craniosynostosis and chondrodysplasia, which severely affect ...

A pair of proteins could contribute to the development of healthy, strong bones by directing early cell movement and blood vessel generation. A pair of proteins, YAP and TAZ, has been identified as ...